^
BIOMARKER:

BCR-ABL1 fusion

i
Other names: BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
BCR-ABL1 fusion
Chronic Myeloid Leukemia
nilotinib
Sensitive
:
A1
SOHO 2022 - 1 week - (New C4)
BCR-ABL1 fusion
Chronic Myeloid Leukemia
dasatinib
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
imatinib
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
ponatinib
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
dasatinib
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
bosutinib
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
imatinib
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
nilotinib
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
bosutinib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
imatinib
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
inotuzumab ozogamicin
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
A2
BCR-ABL1 fusion
Chronic Myeloid Leukemia
Tyrosine kinase inhibitor
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
Tyrosine kinase inhibitor
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
Tyrosine kinase inhibitor
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
bosutinib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
nilotinib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
ponatinib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
brexucabtagene autoleucel
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
etoposide IV
Sensitive
:
B
BCR-ABL1 fusion
Chronic Myeloid Leukemia
asciminib
Sensitive
:
B
BCR-ABL1 fusion
Chronic Myeloid Leukemia
ponatinib
Sensitive
:
C1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
bosutinib + inotuzumab ozogamicin
Sensitive
:
C2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive
:
C3
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
CVAD + Tyrosine kinase inhibitor
Sensitive
:
C3
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
ponatinib + blinatumomab
Sensitive
:
C3
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
ponatinib + blinatumomab
Sensitive
:
C3
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib + blinatumomab
Sensitive
:
C3
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
CAR-T immunotherapy
Sensitive
:
C3
BCR-ABL1 fusion
Myelodysplastic Syndrome
imatinib
Sensitive
:
C4
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
C4